Novel insights into immunotherapy for hepatitis B patients
Sheikh Mohammad Fazle Akbara b✉, Mamun Al‐Mahtabc d, Munira Jahane f, Osamu Yoshidag h, Yoichi Hiasag h
- aa Department of Medical Sciences , Toshiba General Hospital , Tokyo , Japan
- bDepartment of Medical Sciences, Toshiba General Hospital, Tokyo, Japan
- cb Department of Hepatology , Bangabandhu Sheikh Mujib Medical University , Dhaka , Bangladesh
- dDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- ec Department of Virology , Bangabandhu Sheikh Mujib Medical University , Dhaka , Bangladesh
- fDepartment of Virology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- gd Department of Gastroenterology and Metabology , Ehime University Graduate School of Medicine , Toon , Japan
- hDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
The possible use of immunotherapy for hepatitis B has emerged for two major reasons: (1) chronic hepatitis B (CHB) is an immune-mediated pathological condition, and (2) commercially available antiviral drugs are of limited efficacy. Although various immunomodulatory agents have been used to treat patients with CHB during the last three decades, there is currently no consensus among physicians and hepatologists regarding the suitability of immunotherapy for patients with CHB. However, new insights into immunotherapy for CHB have emerged; these may facilitate design of effective and tolerable immunotherapy regimens for these patients. This review provides a comprehensive overview of immunotherapy for CHB.
TL;DRNew insights into immunotherapy for CHB have emerged and these may facilitate design of effective and tolerable immunotherapy regimens for patients with CHB. (Semantic Scholar)